MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ZOM - Zomedica Corp
$2.05
0.16(8.47%)9:00:00 PM 2/24/2021
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/18/2021ZOM
    Here are the tough questions Congress needs to ask about GameStop today

    Yahoo Finance’s Jared Blikre, Brian Sozzi, Julie Hyman, and Myles Udland preview the GameStop Congressional hearing happening today.

    02/16/2021ZOM
    What the GameStop Congressional hearing will reveal to retail investors

    A House Financial Services Committee hearing about the GameStop trading frenzy, scheduled for Feb. 18, will shine a light on Robinhood and stock trading.

    02/16/2021ZOM
    Zomedica Corp. Announces Full Exercise of Over-Allotment Option by Underwriter

    ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the underwriter of its previously announced public offering of has exercised in full its over-allotment option to purchase an additional 13,697,368 common shares of Zomedica at a price to the public of $1.90 per share, less underwriting discounts and commissions. Afte...

    02/12/2021ZOM
    TransEnterix Stock Has Potential, But Wait for a Pullback

    TransEnterix (NYSEAMERICAN:TRXC) is yet another small cap “story stock” that’s gone from zero to sixty. Since January, shares have zoomed from around $1.17 per share, to around $7 per share as of this writing. But, is it just hype pushing shares higher? Or, is there compelling evidence this company, which stumbled massively in 2018 and 2019, is finally ready for prime time? Source: Dmytro Zinkevych / Shutterstock.com Consider it a bit of both. One one hand, recent success its seen with its Senha...

    02/11/2021ZOM
    Zomedica Corp. Announces Closing of $173.5 Million Bought Deal

    ANN ARBOR, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the closing of its previously announced public offering of 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. As previously announced, Zomedica also has granted to the underwriter a 30-day op...

    02/9/2021ZOM
    Zomedica stock tumbles on heavy volume after public stock offering upsized 7-fold 'due to demand'

    Shares of Zomedica Corp. tumbled 17.0% in premarket trading Tuesday, after the veterinary health company's common stock offering, that was upsized by nearly seven-fold, priced at a deep discount. Trading volume of 40.1 million shares made Zomedica's stock the most actively traded ahead of the open. The company said overnight that the sole book-running manager for the offering, H.C. Wainwrite & Co. agreed to increase the size of the public offering "due to demand" to 91.3 million shares at a pric...

    02/9/2021ZOM
    Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million

    ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commi...

    02/8/2021ZOM
    Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares

    ANN ARBOR, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 13,157,895 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts a...